- Home
- XTLB vs FOXO Comparison
XTLB vs FOXO Comparison
Compare XTLB & FOXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTLB
- FOXO
- Stock Information
- Founded
- XTLB 1993
- FOXO 2019
- Country
- XTLB Israel
- FOXO United States
- Employees
- XTLB N/A
- FOXO N/A
- Industry
- XTLB Biotechnology: Pharmaceutical Preparations
- FOXO Retail: Computer Software & Peripheral Equipment
- Sector
- XTLB Health Care
- FOXO Technology
- Exchange
- XTLB Nasdaq
- FOXO Nasdaq
- Market Cap
- XTLB 7.8M
- FOXO 8.0M
- IPO Year
- XTLB 2005
- FOXO N/A
- Fundamental
- Price
- XTLB $1.76
- FOXO $0.28
- Analyst Decision
- XTLB
- FOXO
- Analyst Count
- XTLB 0
- FOXO 0
- Target Price
- XTLB N/A
- FOXO N/A
- AVG Volume (30 Days)
- XTLB 12.8K
- FOXO 8.9M
- Earning Date
- XTLB 02-20-2025
- FOXO 11-19-2024
- Dividend Yield
- XTLB N/A
- FOXO N/A
- EPS Growth
- XTLB N/A
- FOXO N/A
- EPS
- XTLB N/A
- FOXO N/A
- Revenue
- XTLB N/A
- FOXO $1,341,000.00
- Revenue This Year
- XTLB N/A
- FOXO N/A
- Revenue Next Year
- XTLB N/A
- FOXO N/A
- P/E Ratio
- XTLB N/A
- FOXO N/A
- Revenue Growth
- XTLB N/A
- FOXO 196.03
- 52 Week Low
- XTLB $0.77
- FOXO $0.13
- 52 Week High
- XTLB $4.99
- FOXO $1.30
- Technical
- Relative Strength Index (RSI)
- XTLB 50.14
- FOXO 36.31
- Support Level
- XTLB $1.42
- FOXO $0.43
- Resistance Level
- XTLB $1.83
- FOXO $0.34
- Average True Range (ATR)
- XTLB 0.13
- FOXO 0.06
- MACD
- XTLB -0.02
- FOXO -0.03
- Stochastic Oscillator
- XTLB 53.13
- FOXO 3.51
About XTLB XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
About FOXO FOXO Technologies Inc.
FOXO Technologies Inc is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. FOXO's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. The company has two reportable business segments, FOXO Labs and FOXO Life.